Sinusitis News and Research

Latest Sinusitis News and Research

Teva presents new Reslizumab data at European Respiratory Society (ERS) International Congress 2015

Teva Pharmaceutical Industries Ltd., has presented results from a post hoc analysis of two pivotal Phase III clinical trials showing that treatment with reslizumab reduced clinical asthma exacerbations (CAEs) by 75 percent versus placebo in a subgroup of patients with late onset asthma (diagnosed at 40 years of age and older) with elevated blood eosinophils, who were inadequately controlled on inhaled corticosteroids (ICS).

28 Sep 2015

New Medicare payment model reduces use of low-value services

In the first large-scale study to assess the effects of the Affordable Care Act's reforms to physician and hospital payments on the use of wasteful health care services, researchers have found that a new Medicare payment model reduced the number of times patients received services providing little or no health benefit.

22 Sep 2015

Smith & Nephew to distribute Scopis TGS Target Guided Surgery system in the UK, Ireland and Belgium

Smith & Nephew plc, the global medical technology business, today announces a partnership with ScopisGmbH, the German developer and manufacturer of surgical navigation systems, as the exclusive distributor of Scopis TGS Target Guided Surgery system in the UK, Ireland and Belgium from 1 July.

13 Jul 2015

Smith & Nephew becomes exclusive distributor of Scopis TGS system in UK, Ireland and Belgium

8 Jul 2015

Common antibiotic azithromycin effectively kills many multidrug-resistant bacteria

Contrary to current medical dogma, researchers at University of California, San Diego School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences report that the common antibiotic azithromycin kills many multidrug-resistant bacteria very effectively — when tested under conditions that closely resemble the human body and its natural antimicrobial factors.

11 Jun 2015

Switching from Remicade to Inflectra benefits patients with rheumatic diseases

Hospira, Inc., a global leader in biosimilars, today announced the results of an independent clinical study, showing patients with rheumatic diseases experienced comparable clinical effectiveness and safety after switching from Remicade™ to Inflectra.

10 Jun 2015

New telemedicine plan for underinsured, uninsured individuals

The Affordable Care Act helped many become insured, yet 31 million people are "underinsured" with high deductible plans and face out-of-pocket medical costs that can cause serious financial stress.

30 May 2015

Meta-analysis supports ambrisentan efficacy

A meta-analysis supports the efficacy of ambrisentan in patients with pulmonary arterial hypertension.

15 May 2015

Endo announces commercial availability of NATESTO nasal gel for men with hypogonadism

Endo Pharmaceuticals Inc., a subsidiary of Endo International plc (NASDAQ: ENDP) (TSX: ENL), announced today the commercial availability of NATESTO (testosterone nasal gel), the first and only nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism.

16 Mar 2015

Hospira announces launch of first biosimilar monoclonal antibody in Europe

Hospira, Inc., a world leader in the development of biosimilar therapies, today announced the launch of the first biosimilar monoclonal antibody (mAb), Inflectra (infliximab), in major European markets.

16 Feb 2015

Johns Hopkins researchers reveal that e-cigarettes weaken immune system

In a study with mice, Johns Hopkins Bloomberg School of Public Health researchers have found that e-cigarettes compromise the immune system in the lungs and generate some of the same potentially dangerous chemicals found in traditional nicotine cigarettes.

5 Feb 2015

Two new ODYSSEY trials meet primary efficacy endpoints

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that two new ODYSSEY trials, which are the first Phase 3 trials to assess alirocumab administered every four weeks, met their primary efficacy endpoints.

9 Jan 2015

Roche announces launch of cobas Liat System for on-demand testing in different settings

Roche today announced the launch of the cobas Liat System—a fast, compact , easy to use, molecular diagnostic platform, designed for on-demand testing in physician clinics, pharmacies and hospital lab settings.

16 Dec 2014

New diagnostic system describes symptoms using the image of patient's tongue

Physicians often ask their patients to "Please stick out your tongue". The tongue can betray signs of illness, which combined with other symptoms such as a cough, fever, presence of jaundice, headache or bowel habits, can help the physician offer a diagnosis. For people in remote areas who do not have ready access to a physician, a new diagnostic system is reported in the International Journal of Biomedical Engineering and Technology that works to combine the soft inputs of described symptoms with a digital analysis of an image of the patient's tongue.

7 Dec 2014

Endo announces acquisition of rights to Natesto (testosterone nasal gel)

Endo International plc, announced today the acquisition of rights to Natesto (testosterone nasal gel), the first and only testosterone nasal gel for replacement therapy in adult males diagnosed with hypogonadism, from Trimel BioPharma SRL, a wholly-owned subsidiary of Trimel Pharmaceuticals Corporation.

24 Nov 2014

Sanofi, Genzyme announce FDA approval of Lemtrada for treatment of relapsing forms of MS

Sanofi and its subsidiary Genzyme announced today that the U.S. Food and Drug Administration has approved Lemtrada (alemtuzumab) for the treatment of patients with relapsing forms of multiple sclerosis (MS). Because of its safety profile, the use of Lemtrada should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.

17 Nov 2014

Regeneron, Sanofi report positive results from dupilumab Phase 2b study in patients with asthma

Regeneron Pharmaceuticals, Inc. and Sanofi today announced positive results from the interim analysis of a dose-ranging Phase 2b study of dupilumab in adult patients with uncontrolled moderate-to-severe asthma. Dupilumab is an investigational therapy blocking IL-4 and IL-13, two cytokines required for the Th2 immune response.

11 Nov 2014

Regeneron, Sanofi announce initiation of dupilumab Phase 3 study in adults with atopic dermatitis

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the first patients have been dosed in a Phase 3 clinical study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, in adults with moderate-to-severe atopic dermatitis (AD) that is not adequately controlled with topical AD medications.

20 Oct 2014

Sanofi, Regeneron report positive Phase 2 study of dupilumab in patients with CSwNP

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that a Phase 2a proof-of-concept study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, met all primary and secondary endpoints in patients with moderate-to-severe chronic sinusitis with nasal polyps (CSwNP) who did not respond to intranasal corticosteroids.

30 Sep 2014

Acclarent releases ACCLARENT AERA Eustachian Tube Balloon Dilation System for ETD treatment

Acclarent, Inc. announced today the launch of the ACCLARENT AERA Eustachian Tube Balloon Dilation System for the treatment of adult patients with Eustachian Tube Dysfunction (ETD), a condition marked by ear pain, pressure and dulled hearing.

18 Sep 2014

Sinusitis News and Research

Latest Sinusitis News and Research

Teva presents new Reslizumab data at European Respiratory Society (ERS) International Congress 2015

New Medicare payment model reduces use of low-value services

Smith & Nephew to distribute Scopis TGS Target Guided Surgery system in the UK, Ireland and Belgium

Smith & Nephew becomes exclusive distributor of Scopis TGS system in UK, Ireland and Belgium

Common antibiotic azithromycin effectively kills many multidrug-resistant bacteria

Switching from Remicade to Inflectra benefits patients with rheumatic diseases

New telemedicine plan for underinsured, uninsured individuals

Meta-analysis supports ambrisentan efficacy

Endo announces commercial availability of NATESTO nasal gel for men with hypogonadism

Hospira announces launch of first biosimilar monoclonal antibody in Europe

Johns Hopkins researchers reveal that e-cigarettes weaken immune system

Two new ODYSSEY trials meet primary efficacy endpoints

Roche announces launch of cobas Liat System for on-demand testing in different settings

New diagnostic system describes symptoms using the image of patient's tongue

Endo announces acquisition of rights to Natesto (testosterone nasal gel)

Sanofi, Genzyme announce FDA approval of Lemtrada for treatment of relapsing forms of MS

Regeneron, Sanofi report positive results from dupilumab Phase 2b study in patients with asthma

Regeneron, Sanofi announce initiation of dupilumab Phase 3 study in adults with atopic dermatitis

Sanofi, Regeneron report positive Phase 2 study of dupilumab in patients with CSwNP

Acclarent releases ACCLARENT AERA Eustachian Tube Balloon Dilation System for ETD treatment

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Sinusitis News and Research

Latest Sinusitis News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in